Syndax

Syndax is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Guidelines:

[Syndax @Syndax]

On #WorldBloodCancerDay, we shine a light on the importance of expanding access to novel therapies for patients in need. #DYK that most new therapies approved for adults are not tested in children, and for cancer drugs, the average delay between the first clinical trial in adults to the first clinical trial in children is 6.5 years?

Together, we have partnered with @BloodCancerUtd to expand clinical trial access for historically excluded patient groups, including pediatrics.

Learn about what’s possible when science, courage and pediatric patient advocacy come together by watching the below video.

#PassionforPatients

[Syndax @Syndax]

The 2026 @ASCO Annual Meeting (#ASCO26) kicks off tomorrow and Syndax is joining!

Visit us as Booth #26009 to learn how we’re reimagining cancer care:
https://t.co/Ku4mHS8jWK

#HemOnc #Leukemia

[Syndax @Syndax]

#HappeningSoon: Tomorrow, members of Syndax leadership will host a fireside chat at the TD Cowen 7th Annual Oncology Innovation Summit.

Join the webcast at 1:00 p.m. ET to learn what Syndax has in store for #ASCO26 and #EHA2026:
https://t.co/7sqqHTxkMp

A live replay will be available for a limited time.

[Syndax @Syndax]

#NewsAlert: We’re thrilled to announce the acceptance of four revumenib abstracts for presentation at the American Society of Clinical Oncology (@ASCO) Annual Meeting.

Our strong presence at ASCO highlights our scientific leadership and deep commitment to advancing care for patients.

Learn more by accessing the press release below:
https://t.co/2D23Dr6ABy

#ASCO26

[Syndax @Syndax]

During #NationalCancerResearchMonth, we underscore the importance and impact of cancer research in bringing hope to those who need it most.

On the latest episode of the @AACR’s Believe in Progress podcast, Syndax’s Chief Scientific Officer and Founder Dr. Peter Ordentlich discusses what it takes to translate promising science into the future for patients.

Tune in below!

#PassionforPatients

[AACR Foundation @AACRFoundation]

Out now! Dr. Peter Ordentlich, Co-Founder and Chief Scientific Officer of @Syndax, joins the Believe in Progress podcast to discuss the process of taking a hypothesis in a laboratory to a cancer medicine in the clinic. Listen here: https://t.co/jpQDX8OUxv

[Syndax @Syndax]

Today marks #ClinicalTrialsDay, an opportunity to celebrate the enduring spirit of the clinical researchers who continue to adapt, innovate and press forward in service of patients and their families.

Liz, Associate Director, Clinical Operations at Syndax, describes how this shared commitment to the people at the center of every study fuels scientific innovation.

#ResearchRising #WeFlyHigherTogether

[Syndax @Syndax]

#NewsAlert: We’re thrilled to highlight the release of 12 abstracts showcasing new revumenib data on the @EHA_hematology website in advance of the #EHA2026 Congress.

Collectively, these new data highlight our scientific leadership and bolster our confidence that we are positioned to transform the treatment paradigm for patients.

Learn more by accessing the press release below:
https://t.co/AETYAGzNYJ

[Syndax @Syndax]

During #OncologyNursingMonth and on #NationalNursesDay, which marks the start of #NationalNursesWeek, we recognize the power of oncology nurses and the strength they inspire across every stage of cancer care.

Hear from some of our Oncology Clinical Educators on what being a nurse at Syndax means to them.

#WeFlyHigherTogether

[Syndax @Syndax]

During #NationalCancerResearchMonth, we celebrate the transformative impact of cancer research on millions of lives and highlight the critical role of scientists, clinicians and patients in driving innovation forward.

Learn how Syndax is leading the way in reimagining cancer care through bold scientific innovation, collaboration, and our #PassionforPatients in this short video.

#FirstinCompassion

[Syndax @Syndax]

#NewsAlert: Today, we reported our first quarter 2026 financial results and provided a business update.

We delivered over $100 million in combined Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) net sales in the first quarter, highlighting strong demand for our medicines and advancing the company toward profitability.

We are poised for continued commercial growth with robust prescriber bases, excellent payer coverage, and multiple evolving treatment patterns for both medicines.

Learn more by reading our press release and joining our conference call today at 4:30 p.m. ET:
https://t.co/FOTJdjlYSc

A live replay will be available after the call for a limited time.

[Syndax @Syndax]

#MarkYourCalendars: Join us for a conference call and webcast on Thursday, April 30 at 4:30 p.m. ET to hear the Syndax team discuss our first quarter 2026 financial results and provide a business update.

Click the link below for more details:
https://t.co/aSdywKrxVP

A live replay will be available after the call.

[Syndax @Syndax]

#AMLWorldAwarenessDay is an opportunity to join hands with the acute myeloid leukemia (#AML) community to raise awareness and improve the understanding of AML, from early signs and symptoms to survivorship.

Today, we spotlight Sarah, a university administrator from St. Louis, Missouri who courageously shared her patient journey with us.

#PassionforPatients

[Syndax @Syndax]

#DYK that in certain cases, a stem cell transplant, also known as a bone marrow transplant, can be a critical part of blood cancer treatment? During #NationalPediatricTransplantWeek, which kicks off today, we honor pediatric donors and their families for giving patients the gift of a second chance through donation.

At Syndax, we showcase our passion for pediatric patients through our critical work advancing care for this community.

Last month, we hosted a giveback in partnership with Oliver Patch Project, an organization dedicated to uplifting children with pediatric cancers through the power of patches.

Learn more: https://t.co/TfGlbeAYez

#PassionforPatients #FirstinCompassion

[Syndax @Syndax]

The @AACR Annual Meeting (#AACR26) kicks off today, and Syndax is joining!

On Monday, April 20 at 2:15 p.m. PT, Jerry McGeehan, Ph.D., Vice President, Menin Program Team Leader, will take the stage during the AACR Pediatric Cancer Regulatory Science and Policy Session to highlight how Syndax has made strides in advancing pediatric cancer care and participate in a panel discussion alongside other changemakers in healthcare.

See you in San Diego!

#FirstinCompassion #ScientificInnovation

[Syndax @Syndax]

Last year, Alani Floyd, Oncology Account Manager at Syndax, was recognized during @BloodCancerUtd's Visionaries of the Year awards for her enduring impact on the blood cancer community.

Learn about Alani’s personal and professional connection to Blood Cancer United’s mission and how her campaign journey gave her the strength to face her own diagnosis in the below @Forbes article.

#PassionforPatients

[Blood Cancer United @BloodCancerUtd]

Visionaries of the Year are making moves! ✨

Across the country, these candidates are rallying their communities to support breakthrough research, lifesaving advocacy, and free resources.

Learn more about the leaders behind this year’s campaigns on @Forbes: https://t.co/wnxdIkaktY

[Syndax @Syndax]

As we close out #AYAware Week, we’re pleased to announce that Syndax will be attending Stupid Cancer’s #CancerCon for Adolescents & Young Adults, a weekend that brings hundreds of patients, survivors, advocates and health professionals to learn from one another and build community.

Today and always, we’re proud to stand alongside the #AYA community and share our commitment to reimagining cancer care for adolescents and adults.

Access details below:
https://t.co/Ka8zIQtymE

#PassionforPatients #AYACancerAwareness

[Syndax @Syndax]

During #AYAware Week, we share our support for the adolescent and young adult (AYA) cancer community, including the family caregivers who support their AYA family members through their treatment journeys.

Today, we spotlight Caregiver Action Network’s Leukemia Caregiver Guide, a course that connects working caregivers with practical strategies and resources to support both their loved ones and themselves.

Learn more:
https://t.co/JZJzhbeHCC

#PassionforPatients #AYACancerAwareness

[Syndax @Syndax]

Each year, more than 85,000 young people ages 15-39 are diagnosed with cancer in the U.S. At Syndax, our work in reimagining cancer care extends beyond adults and includes both pediatric and adolescent patients.

On the first day of #AYAware Week, also known as #AYACancerAwareness Week, we shine a light on the adolescent and young adult (AYA) cancer community and the unique challenges they face.

Syndax is proud to share resources from our partners at Stupid Cancer that raise awareness and amplify the voices of AYA community members.

Learn more below:
https://t.co/Rst1e85VWt

#PassionforPatients

[Syndax @Syndax]

During #NationalDonateLifeMonth, which kicks off today, we honor #LivingDonorDay, an opportunity to recognize those who have given patients in need a second chance at life through organ and tissue donation.

Today and always, we share our heartfelt gratitude to all donors and celebrate the lives that have been helped because of a donor’s generosity.

#WeFlyHigherTogether
#DonateLifeMonth

[Syndax @Syndax]

#HappeningSoon: Join us for a fireside chat during the Barclays 28th Annual Global Healthcare Conference tomorrow, March 12.

At 11:00 a.m. ET, members of Syndax leadership will take the stage and highlight how we are continuing to deliver on our mission in service of patients.

Access the dial-in details below:
https://t.co/LvYMOXRqdF

A live replay will be available for a limited time.